PDCD1 and neoplasm: These results are consistent with two recent studies showing that that anti‐PD‐1–mediated tumor suppressive activity is primarily dependent of the CD28 costimulatory receptor.103, 104 Both classes of anti‐PD‐1 antibodies also restored calcium mobilization that is downstream of the TCR activation pathway (Figure 4).